An Open-label, Two-period Fixed Sequence Trial to Evaluate the Effect of Multiple Doses of BI 1358894 on the Pharmacokinetics of Bupropion in Healthy Volunteers
Latest Information Update: 20 Sep 2021
Price :
$35 *
At a glance
- Drugs BI 1358894 (Primary) ; Bupropion
- Indications Borderline personality disorders; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Sep 2021 Status changed from active, no longer recruiting to completed.
- 26 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2021 Status changed from not yet recruiting to recruiting.